Braveheart Bio is a technology company.
Braveheart Bio has raised $190.0M across 1 funding round.
Braveheart Bio has raised $190.0M in total across 1 funding round.
Braveheart Bio has raised $190.0M in total across 1 funding round.
Braveheart Bio's investors include Forbion, RA Capital.
Braveheart Bio is a late clinical-stage biotechnology company developing novel small-molecule therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions.[1][6] Its lead candidate, BHB-1893 (licensed as HRS-1893 from Hengrui Pharma), is a selective cardiac myosin inhibitor designed to reduce excessive heart muscle contraction, improving heart performance in patients with obstructive HCM (oHCM), a condition affecting about 1 in 500 people in the US.[1][2][6] The company serves patients with HCM, addressing unmet needs in a market where Bristol Myers Squibb's Camzyos is the first approved therapy, by aiming to establish a new standard of care through late-stage global trials.[1][4][5] Launched in 2025 with $185M in Series A funding from investors like Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences—plus a prior $75M licensing deal—Braveheart shows strong growth momentum, with Phase 1 data presented at ESC 2025 and plans for global Phase 3 trials.[1][2][3]
Braveheart Bio emerged in 2025 as a US-based stealth startup incorporated in Delaware, built around licensing HRS-1893 from China's Jiangsu Hengrui Pharmaceuticals in September 2025.[2][3][4] The deal granted exclusive global rights (excluding Greater China) for $65M upfront (half cash, half equity), plus $10M on tech transfer and up to $1.013B in milestones and royalties, reflecting a "NewCo model" trend where investors back startups on China-originated assets.[2][3][4] CEO Dr. Travis Murdoch, former leader of HI-Bio (acquired by Biogen), brings expertise in advancing clinical programs and company-building.[2][4] The company officially launched on November 5, 2025, with its $185M Series A to fund late-stage development, naming Chris Viehbacher (ex-Novartis CEO) as board chair—pivotal moments signaling rapid traction in cardio biotech.[1][5]
Braveheart rides the wave of China-US biotech dealmaking, where 19+ startups licensed China-discovered drugs in 2025 amid China's rapid clinical progress and US investors' appetite for de-risked assets.[4][5] Timing aligns with HCM market growth—post-Camzyos approval in 2022—fueled by genetic insights into myosin-driven pathology and demand for superior therapies from players like Cytokinetics and Edgewise.[4][6] Market forces favor Braveheart: HCM's prevalence (1 in 500), high unmet need for non-invasive options, and investor surge into cardio (e.g., $185M Series A) amid a shift from immune-oncology.[1][5] It influences the ecosystem by validating the NewCo model, accelerating global access to Chinese innovations, and challenging incumbents in a $10B+ potential market.[2][3][4]
Braveheart is primed to disrupt HCM treatment with BHB-1893's late-stage push, targeting global Phase 3 trials in 2026 backed by $260M+ war chest and elite backers.[1][5] Trends like AI-driven precision cardio, expanding HCM diagnostics, and more China out-licenses will shape its path, potentially yielding approval by 2028-2029 if data confirms differentiation.[2][4] Its influence may grow via partnerships or acquisition, much like Murdoch's prior Biogen exit, solidifying its role in transforming heart failure care from a bold Series A launch.[1][4]
Braveheart Bio has raised $190.0M across 1 funding round. Most recently, it raised $190.0M Series A in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $190.0M Series A | Forbion, RA Capital |